The Meta-Physics Of Meta-Analysis: US FDA’s Curious Framing Of New Safety Guidance
Executive Summary
Long delayed guidance on meta-analysis “will assist sponsors of drug and biological products in designing safety meta-analyses of randomized controlled trials using best practices,” FDA Commissioner says. True – but is that really the point?
You may also be interested in...
Drug Safety Meta-Analyses: US FDA Emphasizes Trial Quality Over Quantity
Three years overdue, agency draft guidance seeks to inject a threshold level of rigor into meta-analyses of randomized, controlled trials to evaluate drug safety and proposes a three-tiered hierarchy of evidence against which FDA will evaluate such studies for regulatory decision-making purposes.
Diabetes Drugs: Longer, Broader Phase II/III Trials Could Replace CV Outcomes Trials, US Panel Says
Premarketing trials that enroll more diverse patient populations and include targeted CV endpoint collection over longer periods of time could be sufficient to allow new type 2 diabetes drugs to reach market without need for a dedicated safety study, advisory committee members say, urging FDA to move away from current two-step approach to cardiovascular risk assessments.
Meta-Analyses After Avandia: FDA Hopes To Set Standards And Controls
FDA is working on a guidance for meta-analysis to support safety reviews, and it clearly hopes to have an impact beyond the walls of White Oak.